echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > Blood test helps predict who might benefit from lung cancer screening

    Blood test helps predict who might benefit from lung cancer screening

    • Last Update: 2022-01-26
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    A blood test, combined with a risk model based on a person's history, more accurately determines who is likely to benefit from lung cancer screening than current U.
    S.
    recommendations, according to a study published today in the Journal of Clinical Oncology by Texas researchers at the University's MD Anderson Cancer Center

    .

    An individualized lung cancer risk assessment, combining blood testing based on a four-marker protein panel developed by MD Anderson and an independent model accounting for smoking history (PLCOm2012), is more robust than the 2021 and 2013 U.
    S.
    Preventive Services Task Force (USPSTF) criteria Sensitive and specific

    .
    Participants in the study were from the Prostate, Lung, Colorectal, and Ovarian (PLCO) screening trial and had a history of at least 10 pack-years of smoking

    .
    If implemented, the blood test plus model would detect 9.
    2% more lung cancer screening cases and reduce non-case screening referrals by 13.
    7% compared to the 2021 USPSTF criteria

    .

    "We recognize that a small percentage of people who qualify for lung cancer screening with annual low-dose CT scans actually do get screened
    .
    Also, CT screening is not readily available in most countries

    .
    Over the years, so, our The goal is to develop a simple blood test that can first identify the need for screening for lung cancer," said Sam Hanash, MD, PhD, professor, clinical cancer prevention and leader at the McCombs Institute for Early Detection and Cancer Detection treatment

    .
    "Our study shows for the first time that a blood test may help identify who might benefit from lung cancer screening

    .
    "

    The United States Prevention Task Force (USPSTF) recommends annual low-dose CT scans for people at high risk of lung cancer, which the 2011 National Lung Screening Trial (NLST) showed could reduce lung cancer mortality
    .
    The 2021 USPSTF criteria are for adults 50 to 80 years of age who have a history of at least 20 pack-year smoking and who either currently smoke or have quit smoking within the past 15 years

    .

    Hanash and his colleagues developed a blood test that combined biomarkers they had previously identified for predicting lung cancer risk
    .
    A multicenter research team used a blinded study to evaluate the binding effect of four protein marker panels to the PLCOm2012 model

    .
    The PLCOm2012 model was independently developed and validated to predict the 6-year risk of lung cancer in current or former smokers

    .

    "When we started doing blood tests, there were many different types of markers," Hanash said
    .
    "Over the past decade, we have done multiple analyses to come up with an inexpensive, simple, and reliable test that has been the guiding principle of our research

    .
    "

    To test the binding of blood markers to the PLCOm2012 model, the researchers analyzed more than 10,000 biological samples from the PLCO study, including 1,299 blood samples from 552 lung cancer patients and 8,709 from 2,193 non-lung cancer patients.
    sample

    .

    In individuals with at least 10 pack-year smoking history, blood tests incorporating the PLCOm2012 model showed overall improved sensitivity (88.
    4% vs 78.
    5%) and specificity (56.
    2% vs 49.
    3%) compared to current USPSTF criteria

    .
    If implemented, the combined personalized risk assessment would identify 105 of the 119 in the PLCO intervention group who received a lung cancer diagnosis within one year

    .

    "Blood tests that identify who could benefit from lung cancer screening are not eligible right now," Hanash said
    .
    "Tens of millions of people around the world could benefit from lung cancer screening

    .
    If you could increase screening eligibility by 5 %, that would be very impactful

    .
    "

    While blood tests could be implemented as a laboratory-developed test in the near future, approval by the U.
    S.
    Food and Drug Administration (FDA) may require evaluation through prospective clinical trials

    .

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.